Zeleciment Rostudirsen
Muscular Dystrophy, Duchenne and Becker Types
Dyne TherapeuticsPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Muscular Dystrophy, Duchenne and Becker Types cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ataluren PTC Therapeutics | Phase 3 | B |
ARG Massachusetts General Hospital | Phase 1 | CC |
Givinostat Italfarmaco | Phase 1 | CC |
MOXIFLOXACIN Italfarmaco | Phase 1 | CC |
Same molecule, other indications
Zeleciment Rostudirsen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →